nach oben

Clinical Pharmacokinetics

Erschienen in:

01.03.2006 | Review Article

Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer

verfasst von: Tessa M. Bosch, Irma Meijerman, Jos H. Beijnen, Jan H. M. Schellens

Erschienen in: Clinical Pharmacokinetics | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

There is wide variability in the response of individuals to standard doses of drug therapy. This is an important problem in clinical practice, where it can lead to therapeutic failures or adverse drug reactions. Polymorphisms in genes coding for metabolising enzymes and drug transporters can affect drug efficacy and toxicity. Pharmacogenetics aims to identify individuals predisposed to a high risk of toxicity and low response from standard doses of anti-cancer drugs. This review focuses on the clinical significance of polymorphisms in drug-metabolising enzymes (cytochrome P450 [CYP] 2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, dihydropyrimidine dehydrogenase, uridine diphosphate glucuronosyltransferase [UGT] 1A1, glutathione S-transferase, sulfotransferase [SULT] 1A1, N-acetyltransferase [NAT], thiopurine methyltransferase [TPMT]) and drug transporters (P-glycoprotein [multidrug resistance 1], multidrug resistance protein 2 [MRP2], breast cancer resistance protein [BCRP]) in influencing efficacy and toxicity of chemotherapy.

The most important example to demonstrate the influence of pharmacogenetics on anti-cancer therapy is TPMT. A decreased activity of TPMT, caused by genetic polymorphisms in the TPMT gene, causes severe toxicity with mercaptopurine. Dosage reduction is necessary for patients with heterozygous or homozygous mutation in this gene.

Other polymorphisms showing the influence of pharmacogenetics in the chemotherapeutic treatment of cancer are discussed, such as UGT1A1*28. This polymorphism is associated with an increase in toxicity with irinotecan. Also, polymorphisms in the DPYD gene show a relation with fluorouracil-related toxicity; however, in most cases no clear association has been found for polymorphisms in drug-metabolising enzymes and drug transporters, and pharmacokinetics or pharmacodynamics of anti-cancer drugs. The studies discussed evaluate different regimens and tumour types and show that polymorphisms can have different, sometimes even contradictory, pharmacokinetic and pharmacodynamic effects in different tumours in response to different drugs.

The clinical application of pharmacogenetics in cancer treatment will therefore require more detailed information of the different polymorphisms in drug-metabolising enzymes and drug transporters. Larger studies, in different ethnic populations, and extended with haplotype and linkage disequilibrium analysis, will be necessary for each anti-cancer drug separately.

Dorne JL. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Fundam Clin Pharmacol 2004 Dec; 18(6): 609–20PubMed

Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 2000 Jun; 10(4): 279–90PubMed

Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer 2004 Feb; 90(4): 747–51PubMed

van den Bongard HJ, Mathot RA, Beijnen JH, et al. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000 Nov; 39(5): 345–67PubMed

de Jonge ME, Huitema AD, Schellens JH, et al. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet 2005; 44(2): 147–73PubMed

Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001 Oct; 11(7): 597–607PubMed

Soyama A, Saito Y, Hanioka N, et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001 Dec; 24(12): 1427–30PubMed

Bahadur N, Leathart JB, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002 Dec; 64(11): 1579–89PubMed

Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002 Mar; 71(3): 196–204PubMed

10.

Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003 Aug; 13(8): 461–72PubMed

11.

Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254(3): 628–31PubMed

12.

Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52(4): 349–55PubMed

13.

Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003; 59(4): 303–12PubMed

14.

van Kuilenburg AB, De Abreu RA, Van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydroge-nase deficiency. Ann Clin Biochem 2003; 40(Pt 1): 41–5PubMed

15.

Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005 May; 77(5): 341–52PubMed

16.

Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002 Apr; 12(3): 251–63PubMed

17.

Chang TK, Yu L, Goldstein JA, et al. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997 Jun; 7(3): 211–21PubMed

18.

Watters JW, Kloss EF, Link DC, et al. A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol 2003 Oct; 95(4): 1352–60PubMed

19.

Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7(1): 59–64PubMed

20.

Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9(5): 539–49PubMed

21.

Ando Y, Price DK, Dahut WL, et al. Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther 2002 Nov; 1(6): 669–73PubMed

22.

Daly AK, Brockmoller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996 Jun; 6(3): 193–201PubMed

23.

Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2D6 allele nomenclature [online]. Available from URL: http://www.imm.ki.se/CYPalleles/cyp2d6.htm [Accessed 2005 Dec 11]

24.

Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997 Aug; 57(16): 3402–6PubMed

25.

Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005 Jan; 97(1): 30–9PubMed

26.

Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23(36): 9312–8PubMed

27.

Relling MV, Evans WE, Fonne-Pfister R, et al. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res 1989 Jan; 49(1): 68–71PubMed

28.

Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP3A4 allele nomenclature [online]. Available from URL: http://www.imm.ki.se/CYPalleles/cyp3a4.htm [Accessed 2005 Dec 11]

29.

Ball SE, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999 Sep; 66(3): 288–94PubMed

30.

Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, et al. Mutation analysis of the human CYP3A4 gene 5′ regulatory region: population screening using non-radioactive SSCP. Mutat Res 2002 Mar; 500(1–2): 103–10PubMed

31.

van Schaik RH, de Wildt SN, van Iperen NM, et al. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 2000 Nov; 46(11): 1834–6PubMed

32.

Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000 Jan; 67(1): 48–56PubMed

33.

Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Human Mutation: mutation in brief no. 191 (1998) [online]. Available from URL: http://www3.interscience.wiley.com/homepages/38515/pdf/mutation/191.pdf [Accessed 2006 Jan 16]

34.

Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002 Sep; 20(17): 3683–90PubMed

35.

Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000 Jul; 68(1): 82–91PubMed

36.

Westlind A, Lofberg L, Tindberg N, et al. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999 May; 259(1): 201–5PubMed

37.

Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001 Dec; 299(3): 825–31PubMed

38.

Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001 Jul; 11(5): 447–58PubMed

39.

Rodriguez-Antona C, Donato MT, Pareja E, et al. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 2001 Sep; 393(2): 308–15PubMed

40.

Miyoshi Y, Ando A, Takamura Y, et al. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 2002 Jan; 97(1): 129–32PubMed

41.

Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998 Oct; 95(22): 13176–81PubMed

42.

Aplenc R, Glatfelter W, Han P, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 2003 Jul; 122(2): 240–4PubMed

43.

Blanco JG, Edick MJ, Hancock ML, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002 Nov; 12(8): 605–11PubMed

44.

Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002 Nov; 54(10): 1271–94PubMed

45.

Hustert E, Zibat A, Presecan-Siedel E, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001 Nov; 29(11): 1454–9PubMed

46.

Koyano S, Kurose K, Saito Y, et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 2004 Jan; 32(1): 149–54PubMed

47.

Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004 Jan; 23(1): 100–7PubMed

48.

Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13(8): 461–72PubMed

49.

Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004 Apr; 5(3): 243–72PubMed

50.

Puisset F, Chatelut E, Dalenc F, et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004 Sep; 54(3): 265–72PubMed

51.

Kishi S, Yang W, Boureau B, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004 Jan; 103(1): 67–72PubMed

52.

Tuchman M, Stoeckeler JS, Kiang DT, et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 1985 Jul; 313(4): 245–9PubMed

53.

Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase: biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988 Jan; 81(1): 47–51PubMed

54.

Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996 Mar; 2(3): 477–81PubMed

55.

Harris BE, Song R, Soong SJ, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990 Jan; 50(1): 197–201PubMed

56.

Fleming RA, Milano G, Thyss A, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992 May; 52(10): 2899–902PubMed

57.

Di Paolo A, Danesi R, Falcone A, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001 Sep; 12(9): 1301–6PubMed

58.

Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994 Nov; 12(11): 2248–53PubMed

59.

Wei X, McLeod HL, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996 Aug; 98(3): 610–5PubMed

60.

Meinsma R, Fernandez-Salguero P, van Kuilenburg AB, et al. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995 Jan; 14(1): 1–6PubMed

61.

van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000 Dec; 6(12): 4705–12PubMed

62.

van Kuilenburg AB, Vreken P, Beex LV, et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 1997 Nov; 33(13): 2258–64PubMed

63.

van Kuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001 May; 7(5): 1149–53PubMed

64.

Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5’-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001 Sep; 7(9): 2832–9PubMed

65.

van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002 Oct; 12(7): 555–8PubMed

66.

Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999 Aug; 5(8): 2006–11PubMed

67.

Maring JG, van Kuilenburg AB, Haasjes J, et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002 Apr; 86(7): 1028–33PubMed

68.

van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002 Sep; 101(3): 253–8PubMed

69.

van Kuilenburg AB, Baars JW, Meinsma R, et al. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann Oncol 2003 Feb; 14(2): 341–2PubMed

70.

Collie-Duguid ES, Etienne MC, Milano G, et al. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000 Apr; 10(3): 217–23PubMed

71.

Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002 Mar; 8(3): 768–74PubMed

72.

Ridge SA, Sludden J, Brown O, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998 Aug; 46(2): 151–6PubMed

73.

Ridge SA, Sludden J, Wei X, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 1998; 77(3): 497–500PubMed

74.

Kouwaki M, Hamajima N, Sumi S, et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998 Dec; 4(12): 2999–3004PubMed

75.

Yamaguchi K, Arai Y, Kanda Y, et al. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001 Mar; 92(3): 337–42PubMed

76.

Innocenti F, Ratain MJ. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls [letter]. Clin Cancer Res 2002 May; 8(5): 1314–6PubMed

77.

Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000 Apr; 6(4): 1322–7PubMed

78.

van Kuilenburg AB, Meinsma R, Zonnenberg BA, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 2003 Oct; 9(12): 4363–7PubMed

79.

Lampe JW, Bigler J, Horner NK, et al. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999 Jun; 9(3): 341–9PubMed

80.

Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc Natl Acad Sci U S A 1998 Jul; 95(14): 8170–4PubMed

81.

Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999 May; 65(5): 576–82PubMed

82.

Fertrin KY, Goncalves MS, Saad ST, et al. Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am J Med Genet 2002 Mar; 108(2): 117–9PubMed

83.

Iolascon A, Faienza MF, Centra M, et al. (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert’s syndrome. Haematologica 1999 Feb; 84(2): 106–9PubMed

84.

Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert’s syndrome: two case reports. Ann Oncol 1997 Oct; 8(10): 1049–51PubMed

85.

Ando Y, Saka H, Asai G, et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998 Aug; 9(8): 845–7PubMed

86.

Raijmakers MT, Jansen PL, Steegers EA, et al. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 2000 Sep; 33(3): 348–51PubMed

87.

Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2(1): 43–7PubMed

88.

Iyer L, Janisch L, Das S, et al. UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan (CPT-11) [abstract no. 690]. Proceedings of the 36th ASCO Annual Meeting; 2000 May 20–23; New Orleans (LA). Alexandria (VA): American Society of Clinical Oncology, 2000: 19

89.

Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000 Dec; 60(24): 6921–6PubMed

90.

Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004 Aug; 91(4): 678–82PubMed

91.

Ando Y, Ueoka H, Sugiyama T, et al. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002 Feb; 24(1): 111–6PubMed

92.

Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004 Mar; 22(8): 1382–8PubMed

93.

Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004 Jun; 75(6): 501–15PubMed

94.

Bomgaars L, Kuttesch N, Bernstein M, et al. Correlation of UGT1A1 promoter genotype with pharmacokinetics and toxicity in pediatric patients receiving irinotecan (CPT-11) [abstract no. 551]. Proceedings of the 39th ASCO Annual Meeting; 2003 May 31–Jun 3; Chicago (IL). Alexandria (VA): American Society of Clinical Oncology, 2003: 138

95.

Chowbay B, Zhou Q, Kibat C, et al. Pharmacogenetics of UGT1A1 and ABCG2 in relation to irinotecan (CPT-11) disposition in Chinese nasopharyngeal carcinoma patients [abstract no. 568]. Proceedings of the 39th ASCO Annual Meeting; 2003 May 31–Jun 3; Chicago (IL). Alexandria (VA): American Society of Clinical Oncology, 2003: 142

96.

Carlini EJ, Raftogianis RB, Wood TC, et al. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 2001 Feb; 11(1): 57–68PubMed

97.

Butcher NJ, Boukouvala S, Sim E, et al. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2002; 2(1): 30–42PubMed

98.

Viezzer C, Norppa H, Clonfero E, et al. Influence of GSTM1, GSTT1, GSTP1, and EPHX gene polymorphisms on DNA adduct level and HPRT mutant frequency in coke-oven workers. Mutat Res 1999; 431(2): 259–69PubMed

99.

Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6(4): 279–90PubMed

100.

Ando M, Kitagawa C, Ando Y, et al. Genetic polymorphisms in the phenobarbital-responisve enhancer module of the UDP-glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity in Japanese patients [abstract no. 496]. Proceedings of the 39th ASCO Annual Meeting; 2003 May 31–Jun 3; Chicago (IL). Alexandria (VA): American Society of Clinical Oncology, 2003: 124

101.

Ciotti M, Basu N, Brangi M, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999 Jun; 260(1): 199–202PubMed

102.

Ando M, Ando Y, Sekido Y, et al. Genetic polymorphisms of UDP-glucuronosyltransferase (UGT) 1A7 gene and irinotecan toxicity in Japanese cancer patients [abstract no. 415]. Proceedings of the 37th ASCO Annual Meeting; 2001 May 12–15; San Francisco (CA). Alexandria (VA): American Society of Clinical Oncology, 2001: 105A

103.

Rammohan M, Jeevananthinee J, Zhou QY, et al. The influence of functional polymorphisms in UGT1A7 and UGT1A9 on irinotecan pharmacokinetics in Asian cancer patients [abstract no. 2007]. Proceedings of the 41st ASCO Annual Meeting; 2005 May 14–17; Orlando (FL). Alexandria (VA): American Society of Clinical Oncology, 2005: 136S

104.

Takahashi T, Fujiwara Y, Yamakido M, et al. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn J Cancer Res 1997 Dec; 88(12): 1211–7PubMed

105.

Strassburg CP, Manns MP, Tukey RH. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 1997 Jul; 57(14): 2979–85PubMed

106.

Coles BF, Morel F, Rauch C, et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001 Nov; 11(8): 663–9PubMed

107.

Sweeney C, Ambrosone CB, Joseph L, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 2003 Mar; 103(6): 810–4PubMed

108.

Stanulla M, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 2000 Feb; 95(4): 1222–8PubMed

109.

Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in Black children with acute lymphoblastic leukemia. Blood 1997 Mar; 89(5): 1701–7PubMed

110.

Autrup JL, Hokland P, Pedersen L, et al. Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia. Eur J Pharmacol 2002 Mar; 438(1–2): 15–8PubMed

111.

Voso MT, D’Alo’ F, Putzulu R, et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 2002 Oct; 100(8): 2703–7PubMed

112.

Dieckvoss BO, Stanulla M, Schrappe M, et al. Polymorphisms within glutathione S-transferase genes in pediatric non-Hodgkin’s lymphoma. Haematologica 2002 Jul; 87(7): 709–13PubMed

113.

Sweeney C, Nazar-Stewart V, Stapleton PL, et al. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003 Jun; 12(6): 527–33PubMed

114.

Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000 Sep; 11(8): 639–43PubMed

115.

Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002 Jun; 94(12): 936–42PubMed

116.

Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000 Oct; 60(20): 5621–4PubMed

117.

Anderer G, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000 Nov; 10(8): 715–26PubMed

118.

Bellincampi L, Ballerini S, Bernardini S, et al. Glutathione transferase P1 polymorphism in neuroblastoma studied by endonuclease restriction mapping. Clin Chem Lab Med 2001 Sep; 39(9): 830–5PubMed

119.

Hamdy SI, Hiratsuka M, Narahara K, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 2003 Jun; 55(6): 560–9PubMed

120.

Nowell S, Sweeney C, Winters M, et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002 Nov; 94(21): 1635–40PubMed

121.

Arylamine N-acetyltransferase (NAT) nomenclature [online]. Available from URL: http://www.louisville.edu/medschool/pharmacology/NAT.html [Accessed 2005 Dec 12]

122.

Butcher NJ, Ilett KF, Minchin RF. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics 1998 Feb; 8(1): 67–72PubMed

123.

Dhaini HR, Levy GN. Arylamine N-acetyltransferase 1 (NAT1) genotypes in a Lebanese population. Pharmacogenetics 2000 Feb; 10(1): 79–83PubMed

124.

Evans DA. N-acetyltransferase. Pharmacol Ther 1989; 42(2): 157–234PubMed

125.

Hickman D, Risch A, Camilleri JP, et al. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992 Oct; 2(5): 217–26PubMed

126.

Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993 Aug; 14(8): 1689–92PubMed

127.

Cascorbi I, Drakoulis N, Brockmoller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995 Sep; 57(3): 581–92PubMed

128.

Ratain MJ, Mick R, Berezin F, et al. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991 Nov; 50(5 Pt 1): 573–9PubMed

129.

Ratain MJ, Mick R, Berezin F, et al. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993 May; 53 (10 Suppl.): 2304–8PubMed

130.

Ratain MJ, Rosner G, Allen SL, et al. Population pharmacodynamic study of amonafide: a cancer and leukemia group B study. J Clin Oncol 1995 Mar; 13(3): 741–7PubMed

131.

Lu KH, Cheng KC, Hsia TC, et al. Paclitaxel affects the amounts of the N-acetylation of 2-aminofluorene and DNA-2-aminofluorene adduct formation in Sprague-Dawley rats. In Vivo 2003 Mar; 17(2): 137–44PubMed

132.

Yang CC, Chen GW, Lu HF, et al. Paclitaxel (taxol) inhibits the arylamine N-acetyltransferase activity and gene expression (mRNA NAT1) and 2-aminofluorene-DNA adduct formation in human bladder carcinoma cells (T24 and TSGH 8301). Pharmacol Toxicol 2003 Jun; 92(6): 287–94PubMed

133.

Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004 Apr; 26(2): 186–91PubMed

134.

Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001 Feb; 34(1): 9–16PubMed

135.

Corominas H, Domenech M, Gonzalez D, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000 Sep; 95(9): 2313–7PubMed

136.

McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. Pharmacogenomics 2002 Jan; 3(1): 89–98PubMed

137.

Krynetski EY, Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A 1995 Feb; 92(4): 949–53PubMed

138.

Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997 Apr; 126(8): 608–14PubMed

139.

Gardiner SJ, Begg EJ, Barclay ML, et al. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxicol Rev 2000 Dec; 19(4): 293–312PubMed

140.

Schutz E, von Ahsen N, Oellerich M. Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, “two-color/shared” anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem 2000 Nov; 46(11): 1728–37PubMed

141.

Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyl-transferase paradigm. Pharm Res 1999 Mar; 16(3): 342–9PubMed

142.

Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyl-transferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996 Apr; 58(4): 694–702PubMed

143.

Ganiere-Monteil C, Medard Y, Lejus C, et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol 2004 Apr; 60(2): 89–96PubMed

144.

Rossi AM, Bianchi M, Guarnieri C, et al. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001 Apr; 57(1): 51–4PubMed

145.

Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998 Oct; 125(4): 879–87

146.

Yan L, Zhang S, Eiff B, et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000 Aug; 68(2): 210–9PubMed

147.

Spire-Vayron de la Moureyre C, Debuysere H, Fazio F, et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 1999 Apr; 9(2): 189–98

148.

Alves S, Amorim A, Ferreira F, et al. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin Pharmacol Ther 2001 Aug; 70(2): 165–74PubMed

149.

Arenas M, Duley JA, Ansari A, et al. Genetic determinants of the pre- and post-azathioprine therapy thiopurine methyltransferase activity phenotype. Nucleosides Nucleotides Nucleic Acids 2004 Oct; 23(8–9): 1403–5PubMed

150.

Marinaki AM, Arenas M, Khan ZH, et al. Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 2003 Feb; 13(2): 97–105PubMed

151.

Lindqvist M, Haglund S, Almer S, et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 2004 Apr; 14(4): 261–5PubMed

152.

Hamdan-Khalil R, Gala JL, Allorge D, et al. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem Pharmacol 2005 Feb; 69(3): 525–9PubMed

153.

Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004 Jul; 14(7): 407–17PubMed

154.

von Ahsen N, Armstrong VW, Oellerich M. Rapid, long-range molecular haplotyping of thiopurine S-methyltransferase (TPMT) *3A, *3B, and *3C. Clin Chem 2004 Sep; 50(9): 1528–34

155.

McLeod HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000 Apr; 14(4): 567–72PubMed

156.

Coulthard SA, Rabello C, Robson J, et al. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Haematol 2000 Sep; 110(3): 599–604PubMed

157.

Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999 Dec; 91(23): 2001–8PubMed

158.

McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999 Jun; 105(3): 696–700PubMed

159.

Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyl-transferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998 Nov; 129(9): 716–8PubMed

160.

Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyl-transferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005 Mar; 293(12): 1485–9PubMed

161.

Dervieux T, Medard Y, Verpillat P, et al. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. Leukemia 2001 Nov; 15(11): 1706–12PubMed

162.

Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000 Apr; 42(4): 628–32PubMed

163.

Baker DE. Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Rev Gastroenterol Disord 2003; 3(3): 150–7PubMed

164.

Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford) 2004 Feb; 43(2): 156–63

165.

Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–98PubMed

166.

Liu Y, Hu M. P-glycoprotein and bioavailability-implication of polymorphism. Clin Chem Lab Med 2000 Sep; 38(9): 877–81PubMed

167.

Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 Mar; 97(7): 3473–8PubMed

168.

Toh S, Wada M, Uchiumi T, et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999 Mar; 64(3): 739–46PubMed

169.

Backstrom G, Taipalensuu J, Melhus H, et al. Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 2003 Apr; 18(5): 359–64PubMed

170.

Nauck M, Stein U, von Karger S, et al. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem 2000 Dec; 46(12): 1995–7PubMed

171.

Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001 Mar; 69(3): 169–74PubMed

172.

Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001 Apr; 11(3): 217–21PubMed

173.

Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001 Aug; 70(2): 189–99PubMed

174.

Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001 Oct; 18(10): 1400–4PubMed

175.

Woodahl EL, Yang Z, Bui T, et al. Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther 2004 Sep; 310(3): 1199–207PubMed

176.

Plasschaert SL, Groninger E, Boezen M, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin Pharmacol Ther 2004 Sep; 76(3): 220–9PubMed

177.

Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998; 42 Suppl.: S44-9

178.

Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003 Aug; 9(9): 3246–53PubMed

179.

Sparreboom A, Marsh S, Mathijssen RH, et al. Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Invest New Drugs 2004 Aug; 22(3): 285–9PubMed

180.

Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002 Sep; 62(17): 4955–62PubMed

181.

Goreva OB, Grishanova AY, Mukhin OV, et al. Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull Exp Biol Med 2003 Aug; 136(2): 183–5PubMed

182.

Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003 May; 22(5): 1117–21PubMed

183.

184.

Efferth T, Sauerbrey A, Steinbach D, et al. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol 2003 Aug; 23(2): 509–17PubMed

185.

Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002 Nov; 54(10): 1311–31PubMed

186.

Kuwano M, Toh S, Uchiumi T, et al. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 1999 Apr; 14(2): 123–31PubMed

187.

Ito K, Suzuki H, Sugiyama Y. Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat MRP2. Mol Pharmacol 2001 May; 59(5): 1077–85PubMed

188.

Wada M, Toh S, Taniguchi K, et al. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/ Dubin-Johnson syndrome. Hum Mol Genet 1998 Feb; 7(2): 203–7PubMed

189.

Tsujii H, Konig J, Rost D, et al. Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin-Johnson syndrome. Gastroenterology 1999 Sep; 117(3): 653–60PubMed

190.

Keitel V, Kartenbeck J, Nies AT, et al. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000 Dec; 32(6): 1317–28PubMed

191.

Kagawa T, Sato M, Hosoi K, et al. Absence of R1066X mutation in six Japanese patients with Dubin-Johnson syndrome. Biochem Mol Biol Int 1999 Apr; 47(4): 639–44PubMed

192.

Mor-Cohen R, Zivelin A, Rosenberg N, et al. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J Biol Chem 2001 Oct; 276(40): 36923–30PubMed

193.

Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001 Mar; 11(2): 175–84PubMed

194.

Moriya Y, Nakamura T, Horinouchi M, et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 2002 Oct; 25(10): 1356–9PubMed

195.

Materna V, Lage H. Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient. J Hum Genet 2003; 48(9): 484–6PubMed

196.

Ito K, Oleschuk CJ, Westlake C, et al. Mutation of TRP1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem 2001 Oct; 276(41): 38108–14PubMed

197.

Young LC, Campling BG, Cole SP, et al. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001 Jun; 7(6): 1798–804PubMed

198.

Demeule M, Brossard M, Beliveau R. Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am J Physiol 1999 Dec; 277(6 Pt 2): F832–40PubMed

199.

Kauffmann HM, Keppler D, Kartenbeck J, et al. Induction of cMRP/cMOAT gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes. Hepatology 1997 Oct; 26(4): 980–5PubMed

200.

Schrenk D, Baus PR, Ermel N, et al. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol Lett 2001 Mar; 120(1–3): 51–7PubMed

201.

Kauffmann HM, Keppler D, Gant TW, et al. Induction of hepatic MRP2 (cMRP/cMOAT) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch Toxicol 1998 Dec; 72(12): 763–8PubMed

202.

Hinoshita E, Uchiumi T, Taguchi K, et al. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 2000 Jun; 6(6): 2401–7PubMed

203.

Tada Y, Wada M, Migita T, et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 2002 Apr; 98(4): 630–5PubMed

204.

Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003 Feb; 9(2): 827–36PubMed

205.

Materna V, Pleger J, Hoffmann U, et al. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 2004 Jul; 94(1): 152–60PubMed

206.

Diestra JE, Scheffer GL, Catala I, et al. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 2002 Oct; 198(2): 213–9PubMed

207.

Bailey-Dell KJ, Hassel B, Doyle LA, et al. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001 Sep; 1520(3): 234–41PubMed

208.

Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 2002 Apr; 1(6): 427–34PubMed

209.

Zamber CP, Lamba JK, Yasuda K, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003 Jan; 13(1): 19–28PubMed

210.

Mitomo H, Kato R, Ito A, et al. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 2003 Aug; 373 (Pt 3): 767–74PubMed

211.

Xu J, Liu Y, Yang Y, et al. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 2004 May; 279(19): 19781–9PubMed

212.

Kruijtzer CM, Beijnen JH, Rosing H, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002 Jul; 20(13): 2943–50PubMed

213.

Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002 Jun; 1(8): 611–6PubMed

214.

Iida A, Saito S, Sekine A, et al. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 2002; 47(6): 285–310PubMed

215.

Honjo Y, Morisaki K, Huff LM, et al. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 2002 Nov; 1(6): 696–702PubMed

216.

Bosch TM, Kjellberg LM, Bouwers A, et al. Detection of SNPs in the ABCG2 gene in a Dutch population. Am J Pharmacogenomics 2005; 5(2): 123–31PubMed

217.

Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004 Mar; 109(2): 238–46PubMed

218.

Sparreboom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004 Jul; 76(1): 38–44PubMed

219.

de Jong FA, Marsh S, Mathijssen RH, et al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 2004 Sep; 10(17): 5889–94PubMed

220.

Ross DD, Yang W, Abruzzo LV, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999 Mar; 91(5): 429–33PubMed

221.

Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002 Jan; 2(1): 48–58PubMed

222.

Sargent JM, Williamson CJ, Maliepaard M, et al. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 2001 Nov; 115(2): 257–62PubMed

223.

van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 2002 May; 16(5): 833–9PubMed

224.

Steinbach D, Sell W, Voigt A, et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002 Aug; 16(8): 1443–7PubMed

225.

Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 2002 Apr; 8(4): 1068–74PubMed

226.

Ross DD, Karp JE, Chen TT, et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000 Jul; 96(1): 365–8PubMed

227.

Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002 Jan; 2(1): 48–58PubMed

228.

van der Kolk DM, Vellenga E, Scheffer GL, et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 2002 May; 99(10): 3763–70PubMed

229.

Kawabata S, Oka M, Soda H, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 2003 Aug; 9(8): 3052–7PubMed

230.

Yoh K, Ishii G, Yokose T, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004 Mar; 10(5): 1691–7PubMed

231.

Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 2001 Apr; 92(4): 452–8PubMed

232.

Scheffer GL, Pijnenborg AC, Smit EF, et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002 May; 55(5): 332–9PubMed

233.

Innocenti F, Undevia SD, Rosner GL, et al. Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes [abstract no. 2006]. Proceedings of the 41st ASCO Annual Meeting; 2005 May 14–17; Orlando (FL). Alexandria (VA): American Society of Clinical Oncology, 2005: 136S

234.

Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004 Feb; 5(1): 11–9PubMed

Titel: Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer
verfasst von: Tessa M. Bosch
Irma Meijerman
Jos H. Beijnen
Jan H. M. Schellens
Publikationsdatum: 01.03.2006
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 3/2006
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200645030-00003

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2006

Effects of Chronic Renal Failure on the Pharmacokinetics of Ruboxistaurin and its Active Metabolite 338522

Quantification of Busulfan in Saliva and Plasma in Haematopoietic Stem Cell Transplantation in Children

Bioavailability of Immediate- and Extended-Release Formulations of Glipizide in Healthy Male Volunteers

Pharmacokinetic and Pharmacodynamic Aspects of Oral Moxifloxacin 400 mg/day in Elderly Patients with Acute Exacerbation of Chronic Bronchitis

Clinical Pharmacokinetics of Docetaxel

Clinical Pharmacology of Cilomilast